Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal is drawing significant interest across the industry.
Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- HP reckons memory chip crunch will linger next year, warns of PC sales slump
- “It has exhausted me”: Kayla Nicole on being measured against Taylor Swift because of her past with Travis Kelce
- Google Ties Suspected Russian Actor to CANFAIL Malware Attacks on Ukrainian Orgs
- Gaudium IVF IPO Day 3: issue subscribed 3.87 times by mid-morning; retail and NII demand remains strong
Source: Original →